For instance, 1,25(OH)2D3, a conventional drug for osteoporosis treatment, can increase Ca2+ absorption but also inhibit TRPV5 expression in osteoclasts, leading to the inhibition of early osteoclast differentiation, activity, and bone loss [120]. This evidence concerns the gene TRPV5 and osteoporosis.